TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Biocytogen and Neurocrine Biosciences Establish Collaborative Agreement for Multi-Target Antibodies

Wednesday, December 20, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKEX: 02315) recently announced an agreement with Neurocrine Biosciences, Inc., involving the assessment of fully human antibodies against specified targets. This collaboration allows Neurocrine Biosciences access to Biocytogen's proprietary RenMice®-derived antibodies, with the option to license selected antibodies for therapeutic product development, manufacturing, and global commercialization. The agreement may also encompass additional targets upon mutual agreement.

As part of the arrangement, if Neurocrine Biosciences chooses to exercise its options, Biocytogen stands to receive option-exercise fees, along with milestone payments for development and commercialization, as well as single-digit royalties on net sales for each chosen target.

Dr. Yuelei Shen, President and CEO of Biocytogen, expressed satisfaction with the recognition of their RenMice®-derived antibodies by Neurocrine Biosciences, a prominent biopharmaceutical company with a focus on neuroscience. Dr. Shen is optimistic about the collaboration's potential to expedite the development of therapies for challenging neurological diseases, leveraging Biocytogen's validated off-the-shelf antibody sequences and Neurocrine's expertise in novel drug development.

Jude Onyia, Ph.D., Chief Scientific Officer at Neurocrine Biosciences, shared excitement about exploring the therapeutic potential of antibodies from Biocytogen's fully human antibody platforms. Dr. Onyia believes that this collaboration will not only expand their pipeline with antibody-based drugs but also contribute to providing improved treatment options for patients.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit